From Bench to Bedside

TrialSite News has spent years documenting a quieter but consequential counter-narrative in gene therapy—one that shifts attention away from prestige approvals and toward who actually gets cured. At the center of that story is San Rocco Therapeutics, whose work with academic partners reflects an access-first philosophy rarely foregrounded in mainstream coverage…

View the rest of the article here

View the PDF